On 24 October 2025, Vaccentis hosted an information event in Zurich for shareholders and investors, attended by over 70 participants. The meeting covered Board of Directors expansion, ongoing project updates, strategic partnerships, and company valuation.
To strengthen the Board, experts Seng Chin Mah and Matt Regan were introduced, detailing their credentials and networks to complement the team. The session began with a market overview, noting strong growth in cancer immunotherapies due to increased incidence and advances in immunotherapy, especially in Asia-Pacific and North America.
Head of R&D Ingrid Rauter reviewed Vaccentis’s technology platform targeting individualized immunotherapies, highlighting progress with product candidate VCC-001.
Vaccentis expanded its structure with Vaccentis Europe GmbH in Vienna, focusing on European and U.S. markets. Strategic alliances, notably with True Med, support clinical and financial growth, accelerating VCC-001's development.
The event concluded with the establishment of objectives and strategies for 2026, as well as comprehensive plans to secure funding for critical initiatives and strengthen Vaccentis’s strategic direction.
